Cognition Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGTX research report →
Range $3 – $3
Price Chart
About the company
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders.
- CEO
- Lisa Ricciardi
- IPO
- 2021
- Employees
- 14
- HQ
- Purchase, NY, US
Get TickerSpark's AI analysis on CGTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $55.37M
- P/E
- -3.73
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 2.05
- EV/EBITDA
- -1.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.57%
- ROIC
- -126.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-47,799,000
- Net Income
- $-23,487,000+30.9%
- EPS
- $-0.32+62.4%
- OCF Growth
- +13.6%
- FCF Growth
- +13.7%
- 52W High
- $1.81
- 52W Low
- $0.55
- 50D MA
- $0.81
- 200D MA
- $1.02
- Beta
- 1.80
- RSI (14)
- 27
- Avg Volume
- 459.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cognition Therapeutics said it aligned with the FDA on a phase III path for zervimesine in DLB, while reporting a modest quarterly loss and cash runway into Q4 2027.· November 5, 2026
- FDA alignment on a registrational phase III trial for zervimesine in dementia with Lewy bodies (DLB) was the key update.
- The planned DLB study will use NPI-2 psychosis symptoms as the primary endpoint, with ADCS-ADL as a key secondary endpoint.
- Management said the trial can be run with less than half the originally considered 750-patient size because of the FDA-agreed endpoint strategy.
- Q3 net loss improved year over year, and the company said cash is sufficient to fund operations and capital expenditures into Q4 2027.
- The START Alzheimer’s study remains fully enrolled and fully funded, with top-line results expected in the second half of 2027.
Cognition reported cash, cash equivalents, and restricted cash equivalents of approximately $31.5 million as of September 30, 2026, plus $18.2 million of remaining obligated NIA grant funds. Q3 2026 R&D expense was $5.1 million versus $3.8 million a year ago; G&A was $2.3 million versus $2.6 million; and net loss was $4.1 million, or $0.04 per basic and diluted share, compared with $4.9 million, or $0.06 per share, in Q3 2025. Management said current cash should fund operations and capital expenditures into Q4 2027. For guidance, the company said it is finalizing the DLB protocol for FDA review, expects to initiate the phase III study in mid-2027, and expects START top-line results in the second half of 2027.
Lisa Ricciardi emphasized that the company reached a regulatory milestone by aligning with the FDA on a phase III path for zervimesine in DLB, calling Cognition the first company to align on a phase III trial for this class in DLB. She stressed that the drug is intended to slow disease progression rather than only treat symptoms, and said the team is now finalizing the protocol, reviewing financing options, and evaluating CRO and site partners. Her tone was upbeat and determined, with a focus on creating a new development path in an area with limited treatment options.
John Doyle reported $31.5 million of cash, cash equivalents, and restricted cash equivalents at September 30, 2026, plus $18.2 million in remaining obligated NIA grant funds. He said R&D rose to $5.1 million from $3.8 million due to higher trial activities with CROs and professional fees, while G&A fell to $2.3 million from $2.6 million because of lower professional fees and compensation. Net loss improved to $4.1 million, or $0.04 per share, from $4.9 million, or $0.06 per share, and he said current cash is enough to fund operations and capital expenditures into Q4 2027.
Analysts focused on DLB trial size, funding, and how the company settled on psychosis-related endpoints. Management said the trial could be meaningfully smaller than the roughly 750-patient design initially contemplated, which would have cost about $150 million, because the FDA agreed that the NPI-2 endpoint and enriched enrollment could support a well-powered registrational study. Questions also centered on what hallucinations and delusions look like in DLB and whether zervimesine could have a safety and competitive advantage versus antipsychotics; management replied that these symptoms are common, measurable, worsen with disease progression, and that zervimesine’s non-antipsychotic profile and lack of expected ARIA risk could be meaningful differentiators.
The biggest positive is regulatory: management says it has FDA alignment on a phase III DLB strategy, which reduces development uncertainty. The company also believes the trial can be run with a moderate sample size, and it continues to highlight a safety profile that could stand out versus the antipsychotics commonly used in DLB.
The company still needs to finalize the protocol, secure sufficient funding, and execute a new phase III program before value can be realized. The DLB path remains challenging because there are no validated biomarkers in the disease, and the company is relying on psychosis as a proxy endpoint, which introduces clinical and regulatory risk. Cash is not ample for a phase III launch by itself, so financing remains a near-term issue despite the runway into Q4 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.9%
- Shares Outstanding
- 95.10M
- Float Shares
- 87.39M
of shares held by institutions
67 13F filers
Buy/sell ratio 0.60. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bios Capital Management, LP | 6.00M | 0 |
| Davenport & Co LLC | 4.25M | ▼ 11.10K |
| Vanguard Capital Management LLC | 3.44M | 0 |
| Vanguard Group Inc | 3.32M | ▲ 635.91K |
| Blackrock, Inc. | 1.25M | ▼ 8.52K |
| Chescapmanager LLC | 997.03K | 0 |
| Geode Capital Management, LLC | 911.53K | ▲ 1.52K |
| Renaissance Technologies LLC | 587.17K | ▼ 106.12K |
| Hilton Capital Management, LLC | 548.95K | 0 |
| Vanguard Fiduciary Trust Co | 508.22K | 0 |
| Cm Management, LLC | 425.00K | ▼ 25.00K |
| Dauntless Investment Group, LLC | 371.70K | ▼ 59.30K |
Held by 23 ETFs
Biggest fund positions in CGTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Khattar Jack A. | other | 25,000 |
| Jun 17, 26 | Monia Brett P | other | 25,000 |
| Jun 17, 26 | Wallace Peggy | other | 25,000 |
| Jun 17, 26 | RICHSTONE ELLEN B | other | 25,000 |
| Jun 17, 26 | Fletcher Aaron G.L. | other | 25,000 |
| May 1, 26 | Doyle John Brendan | other | 8,567 |
| Apr 16, 26 | Doyle John Brendan | buy | 10,000 |
| Apr 16, 26 | Ricciardi Lisa | buy | 9,175 |
| Apr 16, 26 | Caggiano Anthony | buy | 10,000 |
| Feb 15, 26 | Ricciardi Lisa | other | 5,850 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGTX coverage
Recent articles, reports, and earnings notes.
No research on CGTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGTX report →Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
globenewswire.com · Nov 17
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
zacks.com · Nov 10
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
globenewswire.com · Nov 9
Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Cognition Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
globenewswire.com · Nov 5
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
globenewswire.com · Nov 2
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.